Business
Zealand Pharma announces positive Phase 2 results for petrelintide, an amylin analog with potential to redefine the weight management experience for people living with overweight and obesity
Company announcement – No. 3 / 2026 Zealand Pharma announces positive Phase 2 results for petrelintide, an amylin analog with potential to redefine the weight management experience for people living with overweight and obesity Petrelintide achieved up to 10.7% mean body weight reduction at week 42 (versus 1.7% with placebo) and demonstrated placebo-like tolerabilityAt the maximally effective dose, there were no cases of vomiting and no treatment discontinuations due to gastrointestinal adverse e
About this update from Zealand Pharma A/s
[{"type":"image","alt":"Zealand Pharma","displaySize":"","headline":null,"caption":"Zealand Pharma","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":121,"url":"https://media.zenfs.com/en/globenewswire.com/2567d307984f8639b4a7711f51c64eff"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/6gUCOEdJjLHihlE.VvDQtA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE2OTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/2567d307984f8639b4a7711f51c64eff","width":300,"height":121}},"lazy":false},{"type":"text","content":"Company announcement – No. 3 / 2026","length":35,"tagName":"p"},{"type":"text","content":"Zealand Pharma announces positive Phase 2 results for petrelintide, an amylin analog with potential to redefine the weight management experience for people living with overweight and obesity","length":190,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Petrelintide achieved up to 10.7% mean body weight reduction at week 42 (versus 1.7% with placebo) and demonstrated placebo-like tolerability","length":141,"tagName":"p"}]},{"val":[{"type":"text","content":"At the maximally effective dose, there were no cases of vomiting and no treatment discontinuations due to gastrointestinal adverse events","length":137,"tagName":"p"}]},{"val":[{"type":"text","content":"The data reinforce further development of petrelintide in chronic weight management as monotherapy and as a combination partner","length":127,"tagName":"p"}]},{"val":[{"type":"text","content":"Zealand Pharma will host a conference call today at 8:30 PM CET / 2:30 PM ET","length":76,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":481,"olType":false},{"type":"text","content":"Copenhagen, Denmark, March 5, 2026 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today announced positive topline results from the Phase 2 ZUPREME-1 dose-finding trial evaluating investigational petrelintide versus placebo in 493 people living with overweight and obesity (mean baseline BMI of 37 kg/m2; 53% females) for effects on body weight, safety, and tolerability. The trial met its primary endpoint, demonstrating that once-weekly subcutaneous injections of petrelintide (dose-escalated every fourth week) resulted in statistically significant and clinically meaningful reductions in body weight...